PEP-Therapy
Innovative peptides
as targeted therapies for oncology
LATEST NEWS
October 5th, 2021
PEP-Therapy and Institut Curie announce first patients dosed in Phase I clinical trial of PEP-010 for the treatment of advanced solid tumors.
+ READ MORE
July 19th, 2021
PEP-Therapy extends Series-A financing, raising a total of €5.4 million to progress the clinical development of its lead candidate, PEP-010.
+ READ MORE
April 22nd, 2021
PEP-Therapy raises €2.75 million in Series A financing to advance its lead drug candidate in oncology, PEP-010, into clinical trials.
+ READ MORE
